Articles About Earnings

How Proofpoint Could Double Your Investment and Then Double It Again

1 | By Michael A. Robinson

Last Tuesday, I showed you a market-crushing leader that defines high-tech wealth.

The fact is that Proofpoint Inc. (PFPT) is a great way to play the field of anti-phishing cyber security, a major growth field.

But don’t take my word for it. None other than the FBI says these kinds of intrusions cost the American public $12.5 billion in financial damages in the 55 months ended May 2018.

And during that period, early Proofpoint’s stock totally cleaned up. From Nov. 12, 2012, when it closed at $10.22 through its most recent closing high of $130.14 on Oct. 15, 2019, PFPT made 1,173.4%.

Along the way, the stock beat the benchmark S&P 500 by a stunning 902.5%.

Even better, just $25,000 invested in Proofpoint would have turned into $313,350 in only seven years

But don’t worry. I still see plenty of upside ahead. In as little as three years, that original $25,000 will be worth a conservatively estimated $1.27 million.

Let me show you why it’s still not too late to get in on all the action

GW Reports Earnings Monday – But There’s a Much More Profitable Date In Its Near Future

1 | By Michael A. Robinson

We’re getting some big news on Monday.

That’s when GW Pharmaceuticals PLC (Nasdaq: GWPH) is reporting its first-quarter 2018 results. It plans to do so early that the morning of Feb. 5, before the market opens.

GW Pharma is one of the legal marijuana stocks we follow here – so we’ll be waking up early.

GW Pharma’s share price is up 211.3% in the last two years, more than quadruple the performance of the S&P 500 over the same stretch.

Now, GW has disappointed over the past few quarters. In fact, the company posted an earnings per share (EPS) loss of $2.08 for third-quarter 2017. That was 29% below the consensus of the seven analysts who follow it. And Wall Street punished it to the tune of 7% the day those results were released.

And we can expect to see a similar dip if GW again misses expectations on Monday. And if it does, you should see it as an opportunity to buy on the dip and get it at a discount.

That’s because we’re invested here for the long haul – not quarter-to-quarter results – as GW works to get its cannabis-based prescription drugs in American pharmacies.

When it comes to those marijuana-based drugs – and all the profits and share-price gains they’ll soon deliver – there’s a date that’s much more important to us than Feb. 5.

And it’s approaching fast…

These Federal Regulators Are Dead Wrong on Marijuana – Again

0 | By Michael A. Robinson

Not long ago, the U.S. Department of Justice indicated that it would keep on giving leeway to states that have legalized cannabis, even though marijuana remains illegal at the federal level.

Then yesterday, the DOJ hinted that it would begin cracking down on recreational marijuana – and soon.

“In fact, we’re looking at that very hard right now, we had a meeting yesterday and talked about it at some length,” U.S. Attorney General Jeff Sessions said at a press conference yesterday. “It’s my view that the use of marijuana is detrimental, and we should not give encouragement in any way to it, and it represents a federal violation, which is in the law and is subject to being enforced… We are working our way through to a rational policy, but I don’t want to suggest in any way that this department believes that marijuana is harmless and people should not avoid it.”

Bless his heart.

Now I admire Sessions a lot. I’m with him on big priorities like fighting crime… stopping illegal immigration… and supporting local police departments.

But he has been and continues to be dead wrong on legal recreational marijuana.

The genie is out of the bottle.

Facebook Wasn’t the Only Tech Star to Book a Killer Quarter

3 | By Michael A. Robinson

This was supposed to be a lousy quarter for earnings.

But even the dourest of bears are starting to admit that’s not so.

The Wall Street Journal begrudgingly reported that forecasts for second-quarter profits for the S&P 500 came in better than expected.

The leading financial daily said per-share earnings were expected to decline by 2.6% for the period, or less than half the usual forecast for the June quarter.

facebook-app-phoneBut,” the Journal added – relishing the chance to add a sour note to its report – “that is no thanks to the technology sector.”

From where I stand, though, it looks like the good folks at the Journal just don’t know how to analyze technology stocks.

Fact is, four major tech firms just turned in top-shape earnings reports that are further bolstering the market’s post-Brexit rally. (You probably heard about the historic one from Facebook Inc.)

Consider that since the market started bouncing back on June 27 the tech-centric Nasdaq Composite has gained 12.7%. That’s49% better than the S&P 500’s returns.

Do you need further proof – more reasons – that you must be a tech investor if you want to ride the unstoppable trends that will beat the market?

Well, I’ve got four of them…

To continue reading click here.